autologous blood and marrow transplantation - Blog Science ...

Table 2. Patient characteristics (n=42)
Prince et al.
Characteristic n (%)
Age 45 years (range 31-59)
Status at trial entry
Primary metastatic 10 (24%)
Progressed during adjuvant therapy 2 (4%)
Relapsed < 12 mo post adjuvant chemotherapy 11 (26%)
Relapsed > 12 mo post adjuvant chemotherapy 15 (36%)
Locally advanced and refractory chemotherapy 3 (7%)
High-risk adjuvant (>10 nodes) 1 (2%)
Pretransplant status
Sensitive 25 (60%)
Resistant 14 (33%)
Not évaluable 3 (7%)
Disease sites (n=42)
High-risk adjuvant (> 10 nodes) 1
Locally advanced 3
Metastatic 38
Median number of metastatic site 2 (l^t)
Metastatic Sites (n=38)
Nodal/soft tissue only 4
Bone + nodal 7
Visceral ± bone ± nodal 27
Prior treatment
Median number prior regimens 2 (1-5)
Median number prior chemotherapy cycles 8 (1-26)
Prior anthracyclines 29 (70%)
Prior taxanes 14 (33%)
Prior cyclophosphamide 34(81%)
Prior radiotherapy for bone metastases 4 (17%)
Apheresis collections
Mobilization strategies and autograft parameters are detailed in Table 3. Four
patients had an additional mobilization and collection with either the same regimen
or G-CSF alone.
Dose intensity
Of the 42 patients undergoing high-dose therapy, 109 of the planned 126
treatment cycles have been delivered. Twenty-nine patients completed all three
cycles (total cycles 87), nine completed two cycles (total cycles 18), and four
309